QS Research · Michael Burry's Scion Capital analyst template · 2006
BIO-TECHNE Corp (TECH)
As of 2026-11-19 · 12/15 boxes filled from SEC filings and market data
Report price $72.75 (close 2026-11-18); latest close $72.67 (2026-11-20), -0.1% since the report; figures re-marked at the latest close
Conclusion: AVOID
Conviction low · base case -56% · downside -65% · upside +5%
The market is not pricing Bio-Techne's earnings: at $72.75 the stock sits just under the $73.00 per-share Merck KGaA cash offer announced 2026-06-25 and approved by shareholders, so what is being paid for is the deal, not a 66.5x P/E on TTM net income to common against a 29.4x peer median. That is why the call is AVOID, with low conviction: the spread to the offer is merger-arbitrage return, not a fundamentals discount, and the business does not earn the price: revenue fell -0.4% in the fiscal year to 2026-06-30, ROIC of 7.9% sits below the 8.1% WACC, and the reverse DCF needs +10.7% revenue growth a year for ten years. The base case is $32.16 (-55.8%), on a P/E at 29.4x, the peer median P/E (4 peers in the comps table: RVTY 67.2x, A 34.7x, BIO 9.7x, QGEN 24.1x). The downside is $25.73 (-64.6%), on the base case's multiple on -20.0% earnings (the peers trade below the compressed multiple). The upside is $76.39 (+5.0%), on +5% earnings at today's P/E of 66.5x, which requires a bid above the agreed offer.
Key numbers
- Share price: $72.67
- Market cap: $11.42B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $1.23B
- EV / EBITDA (TTM): 34.0x
- P/E (TTM): 66.4x
- FCF yield: 2.7%
- Price / book: 5.27x
- Earnings-quality flags (TTM): none flagged
- EV / FCF (TTM): 37.2x
- Revenue growth (latest fiscal year): -0.4%
- ROIC (TTM): 7.9%
- WACC: 8.1%
- Economic profit spread: -0.1 pts
The 15 boxes
- ✓ 1. Long-form business notes
Bio-Techne is a two-segment life-science tools maker: Protein Sciences (approximately 72% of fiscal 2026 net sales) sells in-house manufactured proteins, antibodies, immunoassays and automated western-blot instruments, while Diagnostics and Spatial Biology (approximately 28%) sells OEM calibrators and controls plus spatial-biology assays and instruments. Revenue rose from $931.0M in fiscal 2021 to $1.22B in fiscal 2026 and $1.23B TTM to 2026-09-30, while operating income ran $298.9M in fiscal 2023, fell to $206.7M in fiscal 2024 and $102.3M in fiscal 2025, then recovered to $251.9M in fiscal 2026 and $240.8M TTM. Cash generation outruns reported earnings: operating cash flow was $292.1M in fiscal 2026 and $337.6M TTM against capex of only $28.9M and $29.4M. The portfolio has been reshaped by M&A (Lunaphore at the start of fiscal 2024; a 19.9% Wilson Wolf stake with the balance due by end-2027) and the second segment was renamed from Diagnostics and Genomics to Diagnostics and Spatial Biology. The company was formerly Techne Corporation and now files as Bio-Techne Corporation; filings under the earlier Techne name are its own.
- ✓ 2. Competitive advantage
The moat is visible in gross margin, not in operating margin: gross profit ran between $632.9M (FY2021) and $807.6M (TTM to 2026-09-30) — roughly 68% of revenue in FY2021 and 65-66% in FY2026/TTM — while operating income swung from $298.9M (FY2023) to $102.3M (FY2025) and back to $251.9M (FY2026). The company claims world leadership in research-grade and cGMP proteins under brands R&D Systems, Tocris, Novus and ProteinSimple, manufactures in-house in North America, the U.K., Canada, Switzerland and China, and introduced over 1,900 new products in fiscal 2026. Competition is fragmented across product lines — the 10-K says no competitor offers all the same lines — and it names competitor categories, not companies, so competitive position is asserted rather than measured. Returns on book equity are modest ($181.8M net income to common on $2.11B total equity, FY2026), reflecting a balance sheet built by acquisition.
- ✓ 3. 10-Q takeaways
Bio-Techne's first quarter of fiscal 2027 (quarter ended September 30, 2026) showed sales of $299.7 million, up 5% reported and 7% organic, with GAAP gross margin flat at 65.6% but adjusted gross margin down to 69.3% as SG&A rose 15%. Protein Sciences grew 9% with a 37.9% operating margin, while Diagnostics and Spatial Biology grew 1% and its operating margin fell to 7.4%. Cash was $350.0 million and first-quarter operating cash flow was $73.1 million, and the pending Merck KGaA merger was approved by shareholders on September 23, 2026. The 10-Q reports no material risk-factor changes from the FY2026 10-K.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.